Risks associated with drug treatments for kidney stones

York, Nadya; Borofsky, Michael S.; Lingeman, James E.

doi:10.1517/14740338.2015.1100604

Cited by 13 publications

(11 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSAID as a standard medication for symptomatic kidney stones [37] have not been described as a strong risk factor for nephrolithiasis. However, animal data demonstrate rapid formation of oxalate stones after application of Cox-2 inhibitors and a high oxalate diet [38].…”

Section: Discussionmentioning

confidence: 99%

Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases

et al. 2017

View full text Add to dashboard Cite

BackgroundGallstones and kidney stones are known complications of inflammatory bowel diseases (IBD). Risk factors have been insufficiently studied and explanatory studies date back up to 30 years. It remains unclear, whether improved treatment options also influenced risk factors for these complications.ObjectivesIdentifying risk factors for gallstones and kidney stones in IBD patients.MethodsUsing data from the Swiss Inflammatory Bowel Disease Cohort Study we assessed associations of diseases characteristics with gallstones and kidney stones in univariate and multivariate logistic regression analyses.ResultsOut of 2323 IBD patients, 104 (7.8%) Crohn’s disease (CD) and 38 (3.8%) ulcerative colitis (UC) patients were diagnosed with gallstones. Significant risk factors for gallstones were diagnosis of CD, age at diagnosis, disease activity and duration, NSAID intake, extra-intestinal manifestations and intestinal surgery. Kidney stones were described in 61 (4.6%) CD and 30 (3.0%) UC patients. Male gender, disease activity, intestinal surgery, NSAID usage and reduced physical activity were significant risk factors. Hospitalization was associated with gallstones and kidney stones. The presence of gallstones increased the risk for kidney stones (OR 4.87, p<0.001).ConclusionThe diagnosis of CD, intestinal surgery, prolonged NSAID use, disease activity and duration and bowel stenosis were significantly associated with cholecystonephrolithiasis in IBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases

et al. 2017

View full text Add to dashboard Cite

show abstract

“… 45 Other side effects which can lead to drug discontinuation in up to one of six patients are postural hypotension, fatigue, gastrointestinal disturbance, weakness, rashes and disarrangement of blood glucose and uric acid levels. 46 , 47 Therefore, patients on thiazides should also be monitored for calcium, potassium, serum levels of uric acid and glucose. Urinary alkalization therapy with potassium citrate or sodium bicarbonate is an essential component of treatment for a variety of stone compositions (calcium oxalate, urate, cystine), with a dual mechanism of action: increase of urinary pH to increase solubility of ions; and increase of urinary citrate, which is a stone inhibitor, to decrease crystallization rate.…”

Section: Metabolic Follow-upmentioning

confidence: 99%

“…5 Gastrointestinal upset is a common side effect, which can be ameliorated when drugs are taken with water and after meals. 47 Although potassium citrate is the most commonly used drug over sodium bicarbonate to avoid fluid retention and increased sodium load, it can lead to life-threatening hyperkalemia in cases of renal failure, necessitating monitoring of serum electrolytes. 47 , 48 Allopurinol, a xanthine oxidase inhibitor, is commonly used to reduce serum and urine urate levels in patients with uric acid urolithiasis.…”

Section: Metabolic Follow-upmentioning

confidence: 99%

“… 47 Although potassium citrate is the most commonly used drug over sodium bicarbonate to avoid fluid retention and increased sodium load, it can lead to life-threatening hyperkalemia in cases of renal failure, necessitating monitoring of serum electrolytes. 47 , 48 Allopurinol, a xanthine oxidase inhibitor, is commonly used to reduce serum and urine urate levels in patients with uric acid urolithiasis. It is a generally safe drug, with gastrointestinal disturbances being the most common side effect, with very rarely observed bone marrow suppression, hepatitis and toxic epidermal necrolysis.…”

Section: Metabolic Follow-upmentioning

confidence: 99%

“…It is a generally safe drug, with gastrointestinal disturbances being the most common side effect, with very rarely observed bone marrow suppression, hepatitis and toxic epidermal necrolysis. 47 In cases of concomitant prescription with thiazides, renal and liver function monitoring is suggested. 47 , 49 In patients with cystinuria and high levels of urinary cystine, thiol-binding drugs are commonly prescribed to convert insoluble cystine molecules to a more soluble product, which is excreted more easily.…”

Section: Metabolic Follow-upmentioning

confidence: 99%

See 2 more Smart Citations

Optimal Delivery of Follow-Up Care for the Prevention of Stone Recurrence in Urolithiasis Patients: Improving Outcomes

Tzelves

Berdempes

Mourmouris

et al. 2022

RRU

View full text Add to dashboard Cite

Urolithiasis is a common clinical condition with frequent recurrences. Advances in knowledge of pathophysiological mechanisms permit the categorization of patients to low and high risk for recurrence, with specific metabolic abnormalities diagnosed in the second category. Follow-up is essential for patients with urolithiasis and consists of both imaging and metabolic follow-up with urine studies. No formal guidelines or solid evidence currently exists regarding frequency and type of follow-up studies to be performed in each category. This review aims to summarize existing evidence regarding follow-up, in order to guide clinicians on how and when to follow-up urolithiasis patients according to existing clinical scenario.

show abstract